کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
10803879 | 1057187 | 2013 | 10 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Mechanisms of resistance to anti-angiogenesis therapies
ترجمه فارسی عنوان
مکانیسم های مقاومت در برابر آنژیوژنز درمان
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
VHLEGFCSCTAMsRTKVEGFREPCPPCmTORPDGFTKIRCCBMDCsPFs - PF هاAkt/PKB - آکت / PKBAutophagy - اتوفاژیVon Hippel–Lindau - از Hippel-LindauProgression free survival - بقای آزاد شدن پیشرفتoverall survival - بقای کلTargeted therapies - درمان های هدفمندcancer stem-like cells - سلول های بنیادی سرطانیbone marrow-derived cells - سلول های مشتق شده از مغز استخوانEndothelial progenitor cells - سلول های پیش ساز اندوتلیالAnti-Angiogenesis - ضد آنژیوژنزepidermal growth factor - عامل رشد اپیدرمیVascular endothelial growth factor - فاکتور رشد اندوتلیال عروقیVascular Endothelial Growth Factor (VEGF) - فاکتور رشد اندوتلیال عروقی (VEGF)platelet-derived growth factor - فاکتور رشد حاصل از پلاکتphosphatase and tensin homolog - فسفاتاز و تنسین همولوگTumor-associated macrophages - ماکروفاژهای مربوط به تومورGist - مشتاقResistance - مقاومتTyrosine kinase inhibitor - مهار کننده تیروزین کینازTAF - می دانمPredictive markers - نشانگرهای پیش بینی شدهmammalian target of rapamycin - هدف پستانداران رپامایسینPten - ژن PTENRenal cell carcinoma - کارسینوم سلول کلیوی یا RCC vascular endothelial growth factor receptor - گیرنده فاکتور رشد اندوتلیال عروقی
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
زیست شیمی
چکیده انگلیسی
Angiogenesis, the formation of new blood vessels from preexisting ones, provides oxygen and nutrients to actively proliferating tumor cells. Hence, it represents a critical aspect of tumor progression and metastasis. Because inhibition of angiogenesis represents a major approach to cancer treatment, the development of inhibitors of angiogenesis is a major challenge. The first FDA approved anti-angiogenic drug bevacizumab, a humanized monoclonal antibody directed against the Vascular Endothelial Growth Factor (VEGF), has been approved for the treatment of metastatic colorectal, lung, breast, and kidney cancers. The encouraging results have lead to the development, in the past few years, of other agents targeting angiogenic pathways as potent anti-cancer drugs and a number of them have been approved for metastatic breast, lung, kidney, and central nervous system cancers. Despite a statistically significant increase in progression free survival, which has accelerated FDA approval, no major benefit to overall survival was described and patients inevitably relapsed due to acquired resistance. However, while progression free survival was increased by only a few months for the majority of the patients, some clearly benefited from the treatment with a real increase in life span. The objective of this review is to present an overview of the different treatments targeting angiogenesis, their efficacy and the mechanisms of resistance that have been identified in different cancer types. It is essential to understand how resistance (primary or acquired over time) develops and how it may be overcome.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Biochimie - Volume 95, Issue 6, June 2013, Pages 1110-1119
Journal: Biochimie - Volume 95, Issue 6, June 2013, Pages 1110-1119
نویسندگان
Sandy Giuliano, Gilles Pagès,